These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 22017695)

  • 1. Adalimumab for the treatment of inflammatory bowel disease.
    Wasan SK; Kane SV
    Expert Rev Gastroenterol Hepatol; 2011 Dec; 5(6):679-84. PubMed ID: 22017695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adalimumab in ulcerative colitis: ready for prime time.
    Danese S
    Dig Liver Dis; 2013 Jan; 45(1):8-13. PubMed ID: 22766323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-TNF-alpha treatment strategies: results and clinical perspectives.
    D'Haens G
    Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S209-16. PubMed ID: 20117344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
    Trinder MW; Lawrance IC
    J Gastroenterol Hepatol; 2009 Jul; 24(7):1252-7. PubMed ID: 19220669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-α therapy during pregnancy: three-center study.
    Bortlik M; Machkova N; Duricova D; Malickova K; Hrdlicka L; Lukas M; Kohout P; Shonova O; Lukas M
    Scand J Gastroenterol; 2013 Aug; 48(8):951-8. PubMed ID: 23834232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methotrexate for psoriasiform lesions associated with anti-tumour necrosis factor therapy in inflammatory bowel disease.
    Buisson A; Cuny JF; Barbaud A; Schmutz JL; Bigard MA; Guéant JL; Peyrin-Biroulet L
    Aliment Pharmacol Ther; 2012 May; 35(10):1175-80. PubMed ID: 22469155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of the tumor necrosis factor antagonists in the treatment of inflammatory bowel disease: an update.
    Leso V; Leggio L; Armuzzi A; Gasbarrini G; Gasbarrini A; Addolorato G
    Eur J Gastroenterol Hepatol; 2010 Jul; 22(7):779-86. PubMed ID: 19786877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A practical, evidence-based guide to the use of adalimumab in Crohn's disease.
    Rubin DT; Panaccione R; Chao J; Robinson AM
    Curr Med Res Opin; 2011 Sep; 27(9):1803-13. PubMed ID: 21809894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases.
    Guerra I; Algaba A; Pérez-Calle JL; Chaparro M; Marín-Jiménez I; García-Castellanos R; González-Lama Y; López-Sanromán A; Manceñido N; Martínez-Montiel P; Quintanilla E; Taxonera C; Villafruela M; Romero-Maté A; López-Serrano P; Gisbert JP; Bermejo F
    J Crohns Colitis; 2012 Jun; 6(5):518-23. PubMed ID: 22398059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Biologic therapies in chronic inflammatory bowel diseases].
    Reenaers C; Louis E; Belaiche J
    Rev Med Liege; 2009; 64(5-6):301-4. PubMed ID: 19642463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Biologic therapies in inflammatory bowel disease: anti-TNF and new therapeutic targets].
    Flamant M; Bourreille A
    Rev Med Interne; 2007 Dec; 28(12):852-61. PubMed ID: 17628232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of anti-TNF therapy in inflammatory bowel disease during pregnancy.
    Khan N; Asim H; Lichtenstein GR
    Expert Opin Drug Saf; 2014 Dec; 13(12):1699-708. PubMed ID: 25406728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Level of adalimumab and its antibody titers define the effectiveness of the biological (anticytokine) therapy in Crohn's disease].
    Lazebnik LB; Sagynbaeva VÉ
    Eksp Klin Gastroenterol; 2013; (7):18-22. PubMed ID: 24772870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selecting appropriate anti-TNF agents in inflammatory bowel disease.
    Yun L; Hanauer S
    Expert Rev Gastroenterol Hepatol; 2009 Jun; 3(3):235-48. PubMed ID: 19485806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor necrosis factor blockade for treatment of inflammatory bowel disease: efficacy and safety.
    Ngo B; Farrell CP; Barr M; Wolov K; Bailey R; Mullin JM; Thornton JJ
    Curr Mol Pharmacol; 2010 Nov; 3(3):145-52. PubMed ID: 20799925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy and safety of Adalimumab in Crohn's disease].
    Serghini M; Haddad W; Jeddi H; Karoui S; Ben Mustapha N; Kallel L; Fekih M; Matri S; Boubaker J; Filali A
    Tunis Med; 2012 Feb; 90(2):101-7. PubMed ID: 22407620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease.
    Herrinton LJ; Liu L; Weng X; Lewis JD; Hutfless S; Allison JE
    Am J Gastroenterol; 2011 Dec; 106(12):2146-53. PubMed ID: 22031357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New and emerging biologics in the treatment of inflammatory bowel disease: quo vadis?
    Danese S; Angelucci E
    Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S217-27. PubMed ID: 20117345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases.
    Roblin X; Marotte H; Rinaudo M; Del Tedesco E; Moreau A; Phelip JM; Genin C; Peyrin-Biroulet L; Paul S
    Clin Gastroenterol Hepatol; 2014 Jan; 12(1):80-84.e2. PubMed ID: 23891927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial.
    Van Assche G; Vermeire S; Ballet V; Gabriels F; Noman M; D'Haens G; Claessens C; Humblet E; Vande Casteele N; Gils A; Rutgeerts P
    Gut; 2012 Feb; 61(2):229-34. PubMed ID: 21948942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.